DaVita Inc. Announces Receipt of DOJ Subpoena
March 06 2005 - 7:30PM
PR Newswire (US)
DaVita Inc. Announces Receipt of DOJ Subpoena EL SEGUNDO, Calif.,
March 6 /PRNewswire-FirstCall/ -- DaVita Inc. (NYSE:DVA), today
announced that it has received a subpoena from the U.S. Department
of Justice, United States Attorney's Office for the Eastern
District of Missouri. The subpoena, which was received on March 4,
2005, requires production of a wide range of documents relating to
the operations of the Company and its subsidiaries from December 1,
1996 to the present. The Company will meet with representatives of
the government to discuss the scope of the subpoena and the
production of responsive documents. (Logo:
http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ) The
subpoena requires the production of documents related to, among
other things, pharmaceutical and other services provided to
patients, relationships with pharmaceutical companies, financial
relationships with physicians and joint ventures. The subject
matter of this subpoena significantly overlaps with the subject
matter of the investigation being conducted by United States
Attorney's Office for the Eastern District of Pennsylvania. This
subpoena has been issued in connection with a joint civil and
criminal investigation. To the Company's knowledge, no proceedings
have been initiated against the Company at this time, although the
Company cannot predict whether or when proceedings might be
initiated. The Company intends to cooperate with the government's
investigation. Kent Thiry, Chairman & CEO of DaVita stated, "We
have worked hard to create and sustain a culture of compliance at
DaVita, as well as the policies and systems to support that
culture. We look forward to the opportunity to answer whatever
questions the government has." Additionally, Mr. Thiry stated,
"This process will have no impact on our plans to acquire Gambro
Healthcare." DaVita will be holding a conference call to discuss
this matter on March 7, 2005, at 10:30 AM Eastern Time. The dial in
number is 800-399-4406. A replay of the conference call will be
available on DaVita's official web page, http://www.davita.com/,
for the following 30 days.
http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO
http://photoarchive.ap.org/ DATASOURCE: DaVita Inc. CONTACT: LeAnne
Zumwalt, Investor Relations of DaVita Inc., +1-310-536-2420 Web
site: http://www.davita.com/
Copyright
DaVita (NYSE:DVA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Jul 2023 to Jul 2024